Document is current

Article History

Accepted: 27 September 2024

First Online: 1 November 2024

Competing interests

: M.M. has received consultancy or advisory board honoraria and speaker’s bureau from Alexion, Amgen, Grifols, Johnson and Johnson Novartis, Sanofi, Sobi and UCB. E.C. has received honoraria (advisory boards, speaker fees) from Novartis, UCB and Sanofi. W.B. has received consultancy or  advisory board honoraria for Agios, Alexion, Amgen, Incyte, Novartis, Roche, Sanofi and SOBI; has received lecture fees or congress support from Alexion, Amgen, Novartis and Sanofi; and has received research support from Alexion. B.F. has received consultancy or advisory board honoraria and speaker’s bureau from Agios, Alexion, Apellis, Janssen, Novartis, Roche, Samsung, Sanofi and Sobi.